Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

Rhea-AI Summary

Strata (Nasdaq: SRTA) entered a secured, asset-based revolving credit agreement with JPMorgan Chase for up to $30.0 million, with an accordion to $50.0 million subject to conditions. The ABL Facility was undrawn at closing and will support future acquisitions. Owned aircraft are excluded from the collateral package and remain unencumbered, preserving financing optionality. Company executives said the facility improves capital efficiency and enables continued tuck-in acquisition execution in the clinical perfusion and organ transplant logistics space.

Positive

• Established a $30.0M asset-based revolving credit facility
• Facility expandable to $50.0M subject to conditions
• Facility was undrawn at close, limiting immediate interest cost
• Owned aircraft excluded from collateral, preserving financing optionality
• Explicit purpose to fund acquisitions and accelerate growth

Negative

• Facility is secured, which may encumber eligible assets (excluding aircraft)
• Expansion to $50.0M is conditional, not guaranteed

News Market Reaction

-6.18%

1 alert

-6.18% News Effect

-$27M Valuation Impact

$405M Market Cap

1K Volume

On the day this news was published, SRTA declined 6.18%, reflecting a notable negative market reaction. This price movement removed approximately $27M from the company's valuation, bringing the market cap to $405M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ABL Facility size: $30.0 million ABL Facility upsizing capacity: $50.0 million

2 metrics

ABL Facility size $30.0 million Secured, asset-based revolving credit facility with JPMorgan Chase Bank

ABL Facility upsizing capacity $50.0 million Maximum size subject to certain conditions in the credit agreement

Market Reality Check

Price: $4.55 Vol: Volume 900,536 is at 0.96...

normal vol

$4.55 Last Close

Volume Volume 900,536 is at 0.96x the 20-day average of 941,049, showing typical trading activity pre-announcement. normal

Technical Shares at 4.69 are trading below the 200-day MA of 4.94 and about 22.09% under the 52-week high.

Peers on Argus

SRTA was down 2.7% while several peers like ASLE (-2.93%), CAAP (-3.18%), and OM...

1 Up

SRTA was down 2.7% while several peers like ASLE (-2.93%), CAAP (-3.18%), and OMAB (-2.39%) also declined. However, momentum data show only UP appearing in scanners and moving up, underscoring a stock‑specific context rather than a broad sector rotation.

Previous Acquisition Reports

1 past event · Latest: Sep 16 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Sep 16	Acquisition announcement	Positive	+8.2%	Completed Keystone Perfusion acquisition with updated 2025 revenue and EBITDA guidance.

Pattern Detected

Past acquisition news coincided with a positive share price reaction.

Recent Company History

Recent history around acquisitions shows Strata using M&A to expand its organ recovery and medical services platform. The September 16, 2025 acquisition of Keystone Perfusion for $124 million added projected $65 million in 2025 revenue and $13 million in Adjusted EBITDA, and the stock moved 8.17% higher the next day. Today’s revolving credit facility supports further acquisition execution within that established strategy.

Historical Comparison

acquisition

+8.2 %

Average Historical Move

Historical Analysis

In the past 12 months, Strata’s only tagged acquisition update saw a 8.17% move, framing expectations around today’s acquisition-focused credit facility.

Typical Pattern

The company moved from acquiring Keystone Perfusion in 2025 to securing a revolving credit facility intended to fund additional acquisitions and extend its M&A playbook.

Market Pulse Summary

The stock moved -6.2% in the session following this news. A negative reaction despite a new credit f...

Analysis

The stock moved -6.2% in the session following this news. A negative reaction despite a new credit facility would contrast with the prior acquisition update that saw shares rise 8.17%. The market may reassess leverage, deal discipline, or integration risk as Strata prepares to fund additional acquisitions using up to $30.0 million, expandable to $50.0 million. Future performance versus guidance tied to past deals like Keystone Perfusion could influence how durable such a decline becomes.

Key Terms

asset-based revolving credit, abl facility, collateral package

3 terms

asset-based revolving credit financial

"entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans"

An asset-based revolving credit is a flexible borrowing facility that lets a company draw, repay and redraw loans up to a limit tied to the value of specific assets—usually things like invoices, inventory or equipment. Think of it as a business credit card secured by items on the company’s balance sheet; investors care because changes in those asset values can shrink available cash quickly, affecting liquidity, borrowing costs and financial risk.

abl facility financial

"may be increased up to an aggregate of $50.0 million (the “ABL Facility”)."

An ABL facility is a line of credit where a company borrows money using its current assets—like accounts receivable, inventory or equipment—as the primary form of security. It works like a home equity line but tied to business assets: the more valuable and easily sold those assets are, the more the company can borrow. Investors watch ABLs because they affect a company’s liquidity, borrowing capacity and financial flexibility, and because repayments depend on the condition and turnover of the underlying assets.

collateral package financial

"Owned aircraft excluded from collateral package and remain unencumbered"

A collateral package is the group of assets a borrower pledges to a lender to secure a loan, such as cash, property, equipment, receivables or shares. It matters to investors because the strength and liquidity of those pledged assets determine how easily a lender can recover value if the borrower defaults, which influences borrowing costs, credit ratings and the risk profile of creditors and equity holders—think of it as the items you leave with a pawn shop to guarantee a loan.

AI-generated analysis. Not financial advice.

• $30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions
• Owned aircraft excluded from collateral package and remain unencumbered
  
  

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”).

“This facility will improve Strata’s capital efficiency, enabling deployment of more cash towards attractive acquisition opportunities,” said Amir Cohen, Strata’s Chief Accounting and Integration Officer. “By leaving our owned aircraft fleet unencumbered, we are maintaining significant optionality for additional financing in the future.”

“We have a strong track record of successful tuck-in acquisitions in the clinical perfusion space,” said Mat Schneider, CFO of Strata’s Clinical division and VP, IR. “This new facility will enable us to continue executing on our time-tested playbook to accelerate growth.”

About Strata Critical Medical, Inc.

Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.

Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.

For more information, visit www.srta.com.

Contacts

Mathew Schneider
investors@srta.com

FAQ

What are the terms of Strata's new ABL Facility (SRTA) announced Feb 5, 2026?

Strata secured a revolving asset-based credit facility of $30.0 million, expandable to $50.0 million under conditions. According to Strata, the facility is secured, was undrawn at close, and is intended to support acquisition activity.

How will the $30M ABL Facility affect Strata (SRTA) acquisition plans?

The facility provides committed capacity to support acquisitions and deploy cash more efficiently. According to Strata, it enables continued execution of their tuck-in acquisition playbook in clinical perfusion and related services.

Is Strata's aircraft fleet encumbered by the new credit agreement (SRTA)?

No, Strata's owned aircraft are explicitly excluded from the collateral package and remain unencumbered. According to Strata, this preserves significant optionality for future financing uses of the fleet.

Can Strata (SRTA) borrow more than $30 million under the facility?

Yes, the facility may be increased to an aggregate of $50.0 million, subject to certain conditions. According to Strata, the accordion feature requires meeting lender and contractual conditions before expansion.

Was the ABL Facility immediately funded when Strata (SRTA) closed the agreement?

No, the ABL Facility was undrawn at closing, so no immediate proceeds were taken. According to Strata, the undrawn status reduces immediate cash interest cost while preserving ready access to borrowing capacity for acquisitions.